Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $738.61 billion. The enterprise value is $769.60 billion.
| Market Cap | 738.61B |
| Enterprise Value | 769.60B |
Important Dates
The next confirmed earnings date is Thursday, May 1, 2025, before market open.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | Feb 14, 2025 |
Share Statistics
Eli Lilly has 897.99 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 897.99M |
| Shares Outstanding | 897.99M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 87.80% |
| Float | 895.35M |
Valuation Ratios
The trailing PE ratio is 70.24 and the forward PE ratio is 35.42. Eli Lilly's PEG ratio is 1.25.
| PE Ratio | 70.24 |
| Forward PE | 35.42 |
| PS Ratio | 16.45 |
| Forward PS | 12.33 |
| PB Ratio | 52.02 |
| P/TBV Ratio | 327.47 |
| P/FCF Ratio | 196.43 |
| P/OCF Ratio | 83.76 |
| PEG Ratio | 1.25 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.94, with an EV/FCF ratio of 204.67.
| EV / Earnings | 72.67 |
| EV / Sales | 17.09 |
| EV / EBITDA | 39.94 |
| EV / EBIT | 43.97 |
| EV / FCF | 204.67 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 2.45.
| Current Ratio | 1.15 |
| Quick Ratio | 0.58 |
| Debt / Equity | 2.45 |
| Debt / EBITDA | 1.79 |
| Debt / FCF | 9.28 |
| Interest Coverage | 22.42 |
Financial Efficiency
Return on equity (ROE) is 84.26% and return on invested capital (ROIC) is 25.29%.
| Return on Equity (ROE) | 84.26% |
| Return on Assets (ROA) | 15.33% |
| Return on Invested Capital (ROIC) | 25.29% |
| Return on Capital Employed (ROCE) | 34.77% |
| Revenue Per Employee | $958,355 |
| Profits Per Employee | $225,319 |
| Employee Count | 47,000 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.26 |
Taxes
In the past 12 months, Eli Lilly has paid $2.09 billion in taxes.
| Income Tax | 2.09B |
| Effective Tax Rate | 16.49% |
Stock Price Statistics
The stock price has increased by +5.70% in the last 52 weeks. The beta is 0.34, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +5.70% |
| 50-Day Moving Average | 842.50 |
| 200-Day Moving Average | 855.91 |
| Relative Strength Index (RSI) | 43.39 |
| Average Volume (20 Days) | 3,479,717 |
Short Selling Information
The latest short interest is 6.36 million, so 0.71% of the outstanding shares have been sold short.
| Short Interest | 6.36M |
| Short Previous Month | 7.08M |
| Short % of Shares Out | 0.71% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 1.72 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $45.04 billion and earned $10.59 billion in profits. Earnings per share was $11.71.
| Revenue | 45.04B |
| Gross Profit | 36.62B |
| Operating Income | 17.50B |
| Pretax Income | n/a |
| Net Income | 10.59B |
| EBITDA | 19.27B |
| EBIT | 17.50B |
| Earnings Per Share (EPS) | $11.71 |
Balance Sheet
The company has $3.43 billion in cash and $34.91 billion in debt, giving a net cash position of -$30.99 billion or -$34.51 per share.
| Cash & Cash Equivalents | 3.43B |
| Total Debt | 34.91B |
| Net Cash | -30.99B |
| Net Cash Per Share | -$34.51 |
| Equity (Book Value) | 14.27B |
| Book Value Per Share | 15.81 |
| Working Capital | 4.36B |
Cash Flow
In the last 12 months, operating cash flow was $8.82 billion and capital expenditures -$5.06 billion, giving a free cash flow of $3.76 billion.
| Operating Cash Flow | 8.82B |
| Capital Expenditures | -5.06B |
| Free Cash Flow | 3.76B |
| FCF Per Share | $4.19 |
Margins
Gross margin is 81.31%, with operating and profit margins of 38.86% and 23.51%.
| Gross Margin | 81.31% |
| Operating Margin | 38.86% |
| Pretax Margin | 28.15% |
| Profit Margin | 23.51% |
| EBITDA Margin | 42.78% |
| EBIT Margin | 38.86% |
| FCF Margin | 8.35% |
Dividends & Yields
This stock pays an annual dividend of $6.00, which amounts to a dividend yield of 0.73%.
| Dividend Per Share | $6.00 |
| Dividend Yield | 0.73% |
| Dividend Growth (YoY) | 15.14% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 51.24% |
| Buyback Yield | -0.09% |
| Shareholder Yield | 0.64% |
| Earnings Yield | 1.43% |
| FCF Yield | 0.51% |
Analyst Forecast
The average price target for Eli Lilly is $1,000.53, which is 21.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,000.53 |
| Price Target Difference | 21.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (5Y) | 18.05% |
| EPS Growth Forecast (5Y) | 33.19% |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 8.41 and a Piotroski F-Score of 6.
| Altman Z-Score | 8.41 |
| Piotroski F-Score | 6 |